Literature DB >> 12007626

A lipoprotein family from Mycoplasma fermentans confers host immune activation through Toll-like receptor 2.

Tsukasa Seya1, Misako Matsumoto.   

Abstract

Mycoplasma have been reported to be associated with human diseases. Three forms of a mycoplasma lipopeptide/protein with the ability to modulate the host immune system were independently identified and named macrophage-activating lipopeptide 2 (MALP-2), P48 and M161Ag (identical to MALP-404). Although these molecules had polypeptides of different sizes, they exerted similar immunomodulatory effects on macrophages/dendritic cells, such as cytokine induction, NO production and maturation of antigen-presenting cells (APCs). M161Ag exhibited complement-activating ability and bound macrophages via complement C3b/C3bi and their receptors. The diacylated N-terminal palmitates were involved in these activities. Toll-like receptor 2 (TLR2) was found to be responsible for these functional features of these mycoplasma products, except for complement activation. Here, we summarize the functional properties of this family of proteins, namely pathogen-associated molecular pattern (PAMP) and discuss its relationship to the reported pathogenesis of latent mycoplasma infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12007626     DOI: 10.1016/s1357-2725(01)00164-9

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  21 in total

1.  Enhancing antitumor immunity perioperatively: a matter of timing, cooperation, and specificity.

Authors:  Jeffrey L Curtis; Antonello Punturieri
Journal:  Am J Respir Cell Mol Biol       Date:  2003-05       Impact factor: 6.914

Review 2.  Interactions between mycoplasma lipid-associated membrane proteins and the host cells.

Authors:  Xiao-xing You; Yan-hua Zeng; Yi-mou Wu
Journal:  J Zhejiang Univ Sci B       Date:  2006-05       Impact factor: 3.066

3.  SHP-1 as a critical regulator of Mycoplasma pneumoniae-induced inflammation in human asthmatic airway epithelial cells.

Authors:  Ying Wang; Zhou Zhu; Tony D Church; Njira L Lugogo; Loretta G Que; Dave Francisco; Jennifer L Ingram; Molly Huggins; Denise M Beaver; Jo Rae Wright; Monica Kraft
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

4.  Anionic pulmonary surfactant lipid regulation of innate immunity.

Authors:  Mari Numata; Pitchaimani Kandasamy; Dennis R Voelker
Journal:  Expert Rev Respir Med       Date:  2012-06       Impact factor: 3.772

5.  Mycoplasma pneumoniae-derived lipopeptides induce acute inflammatory responses in the lungs of mice.

Authors:  Takashi Shimizu; Yutaka Kida; Koichi Kuwano
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

6.  Mycoplasma suppression of THP-1 Cell TLR responses is corrected with antibiotics.

Authors:  Ekaterina Zakharova; Jaykumar Grandhi; Mark D Wewers; Mikhail A Gavrilin
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

7.  Lipid-associated membrane proteins of Mycoplasma fermentans and M. penetrans activate human immunodeficiency virus long-terminal repeats through Toll-like receptors.

Authors:  Takashi Shimizu; Yutaka Kida; Koichi Kuwano
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

8.  Mycoplasma infection induces a scleroderma-like centrosome autoantibody response in mice.

Authors:  I Gavanescu; G Pihan; E Halilovic; E Szomolanyi-Tsuda; R M Welsh; S Doxsey
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 9.  Mycoplasma blood infection in chronic fatigue and fibromyalgia syndromes.

Authors:  Gerhard K M Endresen
Journal:  Rheumatol Int       Date:  2003-07-16       Impact factor: 2.631

10.  Genetic determination of the effect of post-translational modification on the innate immune response to the 19 kDa lipoprotein of Mycobacterium tuberculosis.

Authors:  Katalin A Wilkinson; Sandra M Newton; Graham R Stewart; Adrian R Martineau; Janisha Patel; Susan M Sullivan; Jean-Louis Herrmann; Olivier Neyrolles; Douglas B Young; Robert J Wilkinson
Journal:  BMC Microbiol       Date:  2009-05-14       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.